Kai Wirt@Aktien2022

2Año

I would still keep Novavax and possibly wait that the vlt bring out new vaccines, which can increase sales. I am also in the red with them...🥴

Mostrar original (Alemán)

Me gusta••Respuesta

Leuchtturm@Leuchtturm

2Año

@Aktien2022 what does the company's information say about the development of new vaccines, so long the company is not to be seen as "growth potential"

Mostrar original (Alemán)

Me gusta••Respuesta

Leuchtturm@Leuchtturm

2Año

@Aktien2022 because research is one thing - clinical trials and market approvals are another 🤔.

Mostrar original (Alemán)

Me gusta••Respuesta